With the expiration of API patents, these medicines will now be available at affordable prices

Nectar Life Care has launched a new range of high-quality, cost-effective anti-diabetic formulations, with Dapagliflozin under the brand name DAPNEC. With the expiration of API patents, these medicines will now be available at affordable prices, enhancing accessibility while maintaining high efficacy.

The product portfolio for Nectar ranges from essential anti-diabetic formulations to combination medications, offering comprehensive solutions for Type 2 diabetes management as prescribed by the physician.

 The range also includes:
•                 SITANEC M 50/500 & 50/1000 – Metformin and Sitagliptin Tablets
•                 METNEC-G1 & METNEC G2 – Metformin and Glimepiride Tablets
•                 METNEC 500mg - Metformin Tablets

Manufactured in a WHO-GMP-certified facility, the range is designed to meet international quality standards while ensuring affordability. The company reported Rs 6.4 crore in sales last year and is anticipating to cross the Rs 15 crore mark this year with the introduction of its diabetes care portfolio. This expansion strengthens Nectar Lifecare’s presence in both domestic and international markets, reinforcing its position as a trusted partner for pharmaceutical distributors, exporters, and healthcare providers.

Nilesh Patel, Founder, Nectar Life Care, said, "At Nectar Lifecare, we are committed to addressing this gap. The launch of our cost-effective Dapagliflozin and upcoming diabetic formulations is a step toward ensuring quality diabetes care reaches those who need it most, regardless of financial constraints. Looking ahead, we plan to expand our portfolio with a dedicated anti-obesity range to combat the growing health risks associated with rising obesity. Our goal is to empower individuals to lead healthier lives by making essential treatments both accessible and affordable.”